A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2019
Price : $35 *
At a glance
- Drugs AR 1001 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors AriBio
- 11 Apr 2019 According to an AriBio media release, first patient has been dosed, and enrollment is expected to be completed in Q4 2019.
- 01 Jan 2019 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020.
- 01 Jan 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Jun 2020.